Drugs / [111In]In-DOTA-TCO-trastuzumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07009184 | Dec 2025 → Dec 2026 expected | carcinoma | Radboud University Medical Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [111In]In-DOTA-TCO-trastuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07009184 ↗ |
| Action | Inhibit | “Binding of trastuzumab to HER2-expressing cells suppresses HER2 signaling pathways” NCT07009184 ↗ |
| Route | Intravenous | “intravenously administered radiolabeled (Indium-111) imaging tracer \[111In\]In-DOTA-TCO-trastuzumab” NCT07009184 ↗ |